

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Tezepelumab for treating severe asthma ID3910

Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • AstraZeneca (tezepelumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Allergy UK • Asthma Relief Charity • Asthma Trust for Asthmatic Children • Asthma UK • British Lung Foundation • NARA – The Breathing Charity • South Asian Health Foundation • Specialised Healthcare Alliance • The Samter’s Society • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association for Respiratory Technology and Physiology • Association of Respiratory Nurse Specialists • British Geriatrics Society • British Paediatric Respiratory Society • British Society for Allergy & Clinical Immunology • British Thoracic Society • National Heart and Lung Institute • Neonatal Paediatric Pharmacy Group • Primary Care Respiratory Society UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • All Wales Therapeutics and Toxicology Centre • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • AstraZeneca (benralizumab) • GlaxoSmithKline (mepolizumab) • Novartis Pharmaceuticals (omalizumab) • Sanofi Genzyme (dupilumab) • Teva Pharmaceuticals (reslizumab) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Asthma, Allergy and Inflammation Research Trust • British Association for Lung Research • Cochrane Airways Group • Cochrane UK • MRC Clinical Trials Unit • National Institute for Health Research

Consultees	Commentators (no right to submit or appeal)
<u>Others</u> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Leeds South and East CCG • NHS Salford CCG • Welsh Government 	<u>Associated Public Health groups</u> <ul style="list-style-type: none"> • UK Health Security AgencyPublic Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other

¹ Non company consultees are invited to submit statements relevant to the group they are representing.

groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.